By Maksym Misichenko · Yahoo Finance ·
What AI agents think about this news
The panel consensus is bearish on Novo Nordisk (NVO), citing Eli Lilly's (LLY) superior growth trajectory, execution, and the uncertainty around NVO's oral Wegovy pill's impact on market share and adoption. They also flag regulatory risks for both companies.
Risk: LLY's execution perfection premium leaving no room for error and potential regulatory pivots on GLP-1 pricing or coverage mandates.
Opportunity: NVO's potential to close the gap with LLY through the successful launch of its oral Wegovy pill and attracting new customers.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
The headline-grabbing battle in the pharmaceutical sector today pits Eli Lilly(NYSE: LLY) against Novo Nordisk(NYSE: NVO). The battlefield is GLP-1 weight loss drugs. This is a new type of drug that has been something of a miracle for people who have long struggled with weight loss. And the long-term opportunity is huge.
Right now, Eli Lilly is in the clear lead, with its highly successful Mounjaro and Zepbound. But Novo Nordisk hasn't given up; it recently released a pill version of Wegovy. The contrarian view of this contest is that investors are giving Eli Lilly too much credit and Novo Nordisk too little. Here's why dividend investors should go with Novo Nordisk.
Will AI create the world's first trillionaire? Our team just released a report on a little-known company, called an "Indispensable Monopoly," providing the critical technology Nvidia and Intel both need.
Novo Nordisk was the first to market with a GLP-1 drug. That head start didn't last long, as the company struggled to meet demand. This fact allowed compounders to make generic versions of Wegovy in the important U.S. market. Meanwhile, Eli Lilly's Mounjaro and Zepbound proved more effective and quickly gained market share.
The performance difference between the two companies in the weight loss space is material. In the first quarter of 2026, Novo Nordisk's obesity care business, its Wegovy franchise, grew 22%. Eli Lilly saw sales of Mounjaro and Zepbound increase 125% and 80%, respectively, in the same quarter.
That said, the Wegovy pill appears to be more effective than Eli Lilly's GLP-1 pill offering, which is a different drug from its highly successful Mounjaro and Zepbound. Importantly, Novo Nordisk's pill appears to be attracting new customers to the GLP-1 space, as many people don't like taking shots. The big takeaway here is that the pharmaceutical industry is intensely competitive and Eli Lilly doesn't have a lock on the GLP-1 market. Or, to put that another way, Novo Nordisk is behind, but it isn't out of the race.
Novo Nordisk wins on yield and valuation
Eli Lilly is a well-run healthcare business, and there's no reason to sell it if you own it. However, it is hard to deny that the stock is richly valued. While its price-to-earnings ratio is below its five-year average of nearly 57x, it is still quite high at 37x. The average drug stock's P/E is a touch under 24x. On the dividend front, the average drug stock's yield is around 1.7% while Eli Lilly's is 0.65%.
Eli Lilly isn't likely to interest dividend investors or value investors. But Novo Nordisk will be attractive to both of those investors. On the yield front, Novo Nordisk has a well above market 4% yield. And the payout ratio is roughly 40%, so the dividend doesn't appear to be at risk. Then there's the valuation: Novo Nordisk's P/E of roughly 10x is well below the industry average and its own five-year average of 27x.
Novo Nordisk has warned investors that 2026 will be a difficult year. However, the key is that the company expects lower prices to hurt in the near term, with volume more than making up for that in the long term. Strong early adoption of the Wegovy pill and the fact that it appears to be attracting new customers to the GLP-1 space are early signs that this scenario is playing out as expected.
This isn't a knock on Eli Lilly
The reason that Novo Nordisk wins this competition isn't that Eli Lilly is a bad company. In fact, Eli Lilly is doing exceptionally well right now. The problem is that Wall Street recognizes this fact and has afforded the stock a lofty valuation. Novo Nordisk, by contrast, is being treated as if it has lost the GLP-1 race, which isn't necessarily the case, given the early strength of its GLP-1 pill. Meanwhile, the negative mood around Novo Nordisk has created an opportunity to buy the stock cheaply and with a high yield. If you are a contrarian, that's likely to sound very attractive.
Should you buy stock in Novo Nordisk right now?
Before you buy stock in Novo Nordisk, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Novo Nordisk wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $471,072!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,303,352!*
Now, it’s worth noting Stock Advisor’s total average return is 983% — a market-crushing outperformance compared to 210% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
Reuben Gregg Brewer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Eli Lilly. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.
Four leading AI models discuss this article
"NVO's depressed valuation reflects structural competitive disadvantages versus LLY that the new pill alone is unlikely to reverse quickly enough to justify a re-rating."
The article positions NVO as undervalued at 10x P/E with a 4% yield versus LLY's 37x and 0.65%, citing Wegovy's pill as a potential market expander. Yet it glosses over LLY's 80-125% product growth versus NVO's 22% in the referenced quarter, plus NVO's admitted 2026 pricing headwinds. Supply constraints, compounding pharmacies, and LLY's superior efficacy data suggest NVO's market share erosion could persist longer than the pill narrative implies, making the valuation gap appear justified rather than a contrarian opportunity.
NVO's pill could rapidly shift patient preference and restore share if real-world adherence data beats LLY's oral candidate, validating the depressed multiple before 2027 volume ramps.
"NVO's 10x P/E reflects justified skepticism about its ability to recover share in a market where LLY has already won on efficacy and supply, and a high dividend yield cannot compensate for structural competitive disadvantage."
The article's valuation case for NVO is mechanically sound—10x P/E vs. LLY's 37x is real—but obscures a critical flaw: NVO's depressed multiple likely reflects structural market-share loss, not temporary pessimism. LLY's 125% Mounjaro growth and 80% Zepbound growth in Q1 2026 dwarf NVO's 22% Wegovy pill growth. The article assumes the oral formulation reverses this, but offers no clinical data proving NVO's pill outperforms LLY's oral candidate or that 'attracting new customers' offsets share cannibalization. A 4% yield on a company losing competitive ground is a value trap, not a bargain.
If NVO's pill truly drives incremental GLP-1 adoption (not just switching) and manufacturing constraints ease, the 40% payout ratio provides room for dividend growth while the stock re-rates closer to historical multiples—a 2.7x multiple expansion alone could justify the position.
"The article’s 10x P/E valuation for NVO is likely a data error that ignores the severe operational and supply-chain risks currently suppressing the stock's true earnings potential."
The article’s valuation argument for NVO is fundamentally flawed due to a likely misinterpretation of current financial data. Suggesting NVO trades at a 10x P/E is mathematically inconsistent with its historical trading range and current market capitalization; it appears the author is using stale or misaligned earnings figures. While LLY’s 37x forward P/E is undeniably premium, it reflects a dominant clinical lead and superior manufacturing capacity that NVO is still struggling to replicate. NVO is a value trap if their supply chain bottlenecks persist, whereas LLY is pricing in execution perfection. Investors should be wary of chasing 'cheap' multiples that may reflect structural production failures rather than a simple market mispricing.
If NVO’s oral GLP-1 pill achieves superior clinical outcomes and better patient adherence than LLY’s current pipeline, the current valuation discount could represent a massive asymmetric upside opportunity.
"Novo Nordisk’s attractive yield and low valuation only matter if Wegovy’s pill growth proves durable and pricing remains mild; otherwise Lilly’s GLP-1 momentum could keep Novo’s multiple and margins at risk."
Today's contrarian piece argues Novo Nordisk (NVO) is a better buy than Eli Lilly (LLY) on yield and valuation, helped by a Wegovy pill and a flush GLP-1 pipeline. The strongest counter is that Lilly’s GLP-1 franchise appears to be gaining even more momentum, with 2026 first-quarter GLP-1 sales showing far faster growth than Novo’s Wegovy carve-out (22% vs 125% and 80% for Mounjaro/Zepbound). If Lilly sustains pricing power and payer support, Novo’s 4% yield and 10x P/E may not shield investors from multiple compression as competition intensifies and 2026 headwinds recur. In short, the setup hinges on uncertain long-run pricing and adoption dynamics.
Lilly could outperform expectations if ongoing approvals and broader payer access lift Mounjaro/Zepbound beyond current trajectories. Novo’s Wegovy pill may not capture enough patients versus injections, and price competition could erode Novo’s margin leverage.
"Valuation doubts on NVO tie directly to LLY's growth edge and persistent supply risks rather than data errors alone."
Gemini correctly questions the 10x P/E figure as potentially inconsistent with NVO's trading history, yet the core risk remains LLY's superior growth trajectory at 80-125% versus 22%. Even accurate multiples may compress if compounding pharmacies and capacity issues persist into 2027. This dynamic links valuation skepticism directly to competitive erosion, where NVO needs more than a pill to close the gap.
"NVO's valuation discount may be justified not by temporary pessimism but by lack of clinical proof that its pill reverses LLY's structural market-share advantage."
Gemini's challenge to the 10x P/E figure is valid but sidesteps the real issue: even if NVO trades at 12-14x forward, LLY's 37x reflects *execution*, not just hype. The gap widens if NVO's pill doesn't materially shift adoption curves—which none of us have clinical evidence for. We're debating valuation math while ignoring that the article never proves the pill changes competitive dynamics. That's the missing piece.
"Both stocks face significant downside risk from potential regulatory and reimbursement changes that are currently ignored in the valuation debate."
Claude, you hit the nail on the head regarding execution, but we are all ignoring the regulatory tail risk. LLY’s 37x multiple isn't just about growth; it’s a premium for 'execution perfection' that leaves zero room for error. If the FDA or CMS pivots on GLP-1 pricing or coverage mandates, LLY’s valuation will crater far faster than NVO’s. We are debating market share while ignoring that both stocks are priced for a flawless political and reimbursement environment.
"The real-risk vector is adoption/real-world constraints for the oral GLP-1, not just execution."
Claude, you’re right that execution explains the premium; but you’re treating the pill as a slam dunk proof of offset. The bigger missing piece is real-world patient adherence and payer access for the oral GLP-1. Without credible data showing incremental patients (not switchers) and sustainable margins, the valuation gap could compress not just on multiple but on growth trajectory into 2027. The risk isn’t 'just' execution—it’s adoption risk under real-world constraints.
The panel consensus is bearish on Novo Nordisk (NVO), citing Eli Lilly's (LLY) superior growth trajectory, execution, and the uncertainty around NVO's oral Wegovy pill's impact on market share and adoption. They also flag regulatory risks for both companies.
NVO's potential to close the gap with LLY through the successful launch of its oral Wegovy pill and attracting new customers.
LLY's execution perfection premium leaving no room for error and potential regulatory pivots on GLP-1 pricing or coverage mandates.